Mycophenolate mofetil for maintenance therapy in kidney transplantation

Thomas A. Gonwa

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Mycophenolate mofetil (MMF) is a new immunosuppressive drug that selectively inhibits de novo purine synthesis. It has been tested in three large double-blind controlled trials for the prevention of rejection in renal transplant patients. These studies indicate that the use of MMF dramatically decreases the incidence of biopsy-proven rejection, the use of multiple courses of steroids for rejection, and the use of antilymphocyte preparations for treatment of rejection. The drug was well tolerated with an acceptable safety profile. The main side effects were gastrointestinal (nausea, vomiting, diarrhea), but seldom resulted in the cessation of drug therapy. Hematologic side effects similar to those with azathioprine occurred and were reversible. There was a slight increase in CMV-invasive disease with the use of MMF, but no deaths. Rates of malignancy were within published ranges for transplant recipients. Mycophenolate mofetil is a safe and efficacious drug for prevention of rejection in kidney transplant recipients.

Original languageEnglish (US)
Pages (from-to)128-130
Number of pages3
JournalClinical Transplantation
Volume10
Issue number1 II
StatePublished - Feb 1996
Externally publishedYes

Fingerprint

Mycophenolic Acid
Kidney Transplantation
Pharmaceutical Preparations
Kidney
Azathioprine
Therapeutics
Immunosuppressive Agents
Nausea
Vomiting
Diarrhea
Steroids
Transplants
Biopsy
Safety
Drug Therapy
Incidence
Neoplasms
Transplant Recipients

Keywords

  • Kidney transplantation
  • Mycophenolate mofetil
  • Rejection

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Mycophenolate mofetil for maintenance therapy in kidney transplantation. / Gonwa, Thomas A.

In: Clinical Transplantation, Vol. 10, No. 1 II, 02.1996, p. 128-130.

Research output: Contribution to journalArticle

Gonwa, Thomas A. / Mycophenolate mofetil for maintenance therapy in kidney transplantation. In: Clinical Transplantation. 1996 ; Vol. 10, No. 1 II. pp. 128-130.
@article{e52815d09bdb4f83a6511083b287ac6e,
title = "Mycophenolate mofetil for maintenance therapy in kidney transplantation",
abstract = "Mycophenolate mofetil (MMF) is a new immunosuppressive drug that selectively inhibits de novo purine synthesis. It has been tested in three large double-blind controlled trials for the prevention of rejection in renal transplant patients. These studies indicate that the use of MMF dramatically decreases the incidence of biopsy-proven rejection, the use of multiple courses of steroids for rejection, and the use of antilymphocyte preparations for treatment of rejection. The drug was well tolerated with an acceptable safety profile. The main side effects were gastrointestinal (nausea, vomiting, diarrhea), but seldom resulted in the cessation of drug therapy. Hematologic side effects similar to those with azathioprine occurred and were reversible. There was a slight increase in CMV-invasive disease with the use of MMF, but no deaths. Rates of malignancy were within published ranges for transplant recipients. Mycophenolate mofetil is a safe and efficacious drug for prevention of rejection in kidney transplant recipients.",
keywords = "Kidney transplantation, Mycophenolate mofetil, Rejection",
author = "Gonwa, {Thomas A.}",
year = "1996",
month = "2",
language = "English (US)",
volume = "10",
pages = "128--130",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "1 II",

}

TY - JOUR

T1 - Mycophenolate mofetil for maintenance therapy in kidney transplantation

AU - Gonwa, Thomas A.

PY - 1996/2

Y1 - 1996/2

N2 - Mycophenolate mofetil (MMF) is a new immunosuppressive drug that selectively inhibits de novo purine synthesis. It has been tested in three large double-blind controlled trials for the prevention of rejection in renal transplant patients. These studies indicate that the use of MMF dramatically decreases the incidence of biopsy-proven rejection, the use of multiple courses of steroids for rejection, and the use of antilymphocyte preparations for treatment of rejection. The drug was well tolerated with an acceptable safety profile. The main side effects were gastrointestinal (nausea, vomiting, diarrhea), but seldom resulted in the cessation of drug therapy. Hematologic side effects similar to those with azathioprine occurred and were reversible. There was a slight increase in CMV-invasive disease with the use of MMF, but no deaths. Rates of malignancy were within published ranges for transplant recipients. Mycophenolate mofetil is a safe and efficacious drug for prevention of rejection in kidney transplant recipients.

AB - Mycophenolate mofetil (MMF) is a new immunosuppressive drug that selectively inhibits de novo purine synthesis. It has been tested in three large double-blind controlled trials for the prevention of rejection in renal transplant patients. These studies indicate that the use of MMF dramatically decreases the incidence of biopsy-proven rejection, the use of multiple courses of steroids for rejection, and the use of antilymphocyte preparations for treatment of rejection. The drug was well tolerated with an acceptable safety profile. The main side effects were gastrointestinal (nausea, vomiting, diarrhea), but seldom resulted in the cessation of drug therapy. Hematologic side effects similar to those with azathioprine occurred and were reversible. There was a slight increase in CMV-invasive disease with the use of MMF, but no deaths. Rates of malignancy were within published ranges for transplant recipients. Mycophenolate mofetil is a safe and efficacious drug for prevention of rejection in kidney transplant recipients.

KW - Kidney transplantation

KW - Mycophenolate mofetil

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=0029919822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029919822&partnerID=8YFLogxK

M3 - Article

C2 - 8680049

AN - SCOPUS:0029919822

VL - 10

SP - 128

EP - 130

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 1 II

ER -